Adaptive biotechnologies chief commercial officer sells $32,265 in shares.

Susan Bobulsky, the Chief Commercial Officer of Adaptive Biotechnologies, sold a total of 1,195 shares of the company's stock on September 15, 2026. The transaction, conducted according to a pre-arranged Rule 10b5-1 trading plan, generated $32,265 in proceeds at a price of $27 per share. Since the sale, the stock has appreciated to $28.55, nearing the stock's 52-week high of $28.72 and representing a substantial 107% return over the past year.

However, according to InvestingPro's analysis, the stock appears to be overvalued at its current level, based on its Fair Value assessment. Investors can find the latest list of overvalued stocks, along with 14 additional InvestingPro Tips for Adaptive Biotechnologies, to aid in their investment decisions.

In addition to the share sale, Adaptive Biotechnologies reported its second-quarter financial results on the same day. The company reported an adjusted loss of $0.25 per share, which was higher than the estimated loss of $0.14 per share. Despite the loss, the company's revenue of $71.6 million exceeded the analyst consensus estimate of $65.8 million, reflecting a 22% increase compared to the previous year's revenue of $58.7 million.

Analyst sentiment towards the company remains positive, with notable updates from Guggenheim and BTIG. Guggenheim raised its price target for Adaptive Biotechnologies to $25 from $22, maintaining a 'Buy' rating, citing the company's strong performance in volumes and increased usage among existing clonoSEQ users. Similarly, BTIG raised its price target to $25 from $24, recognizing a 49% year-over-year revenue growth in its core minimal residual disease business.

The clonoSEQ MRD test franchise has experienced a 43% year-over-year volume growth, further underscoring the company's growth potential. These developments highlight the significant interest and confidence analysts have in Adaptive Biotechnologies' growth trajectory.